|
|
|
Novartis
Licensing Cytos’ Anti-Smoking Vaccine for $500M
|
|
|
| April
25, 2007--Cytos
Biotechnology is granting Novartis the worldwide exclusive
rights for CYT002-NicQb, a therapeutic vaccine in Phase II
clinical development for treatment of nicotine addiction.
Under the agreement, Novartis is responsible for
late-stage clinical development, manufacturing, and
commercialization of the vaccine. Cytos Biotechnology is
eligible to receive up to $500 million in upfront and
potential milestone payments, and will also receive
royalties on net sales of products. Cytos
Biotechnology
|
|
|
|
|
|
|
